Catégorie : Neurobiologie

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes, Ethan B. Russo, 2016

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes Ethan B. Russo Cannabis and Cannabinoid Research, 2016, 1, 1, 154-165. DOI: 10.1089/can.2016.0009   Abstract : Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. The commonality in symptomatology in these conditions displaying hyperalgesia [...]

Lire la suite

Dossier : le Cannabis et la vision, Le Cannabiste.com, 2018

Dossier : le Cannabis et la vision Le Cannabiste.com https://lecannabiste.com/dossier-le-cannabis-et-la-vision/ 4 juillet 2018 jean-pierre Si vous posez la question à des utilisateurs réguliers de Cannabis, la plupart vous répondra que l’usage de cette plante constitue pour eux une source de confort et de bien-être. Pour autant nous savons tous que l’usage du Cannabis n’est pas sans incidence sur le corps humain. Les implications du Cannabis sur l’organisme sont nombreuses et parfois plus complexes qu’il n’y paraît. Dans cet article nous nous allons nous intéresser de plus près à l’état des connaissances et aux événements marquants qui ont émaillé la recherche dans le domaine si particulier, [...]

Lire la suite

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders : From Pathogenesis to a Promising Therapeutic Target, Tommaso Cassano et al., 2017

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders : From Pathogenesis to a Promising Therapeutic Target Tommaso Cassano, Silvio Calcagnini, Lorenzo Pace, Federico De Marco, Adele Romano and Silvana Gaetani Frontiers in Neuroscience, 2017, 11, article 30 DOI : 10.3389/fnins.2017.00030   Abstract : As a consequence of an increasingly aging population, the number of people affected by neurodegenerative disorders,such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, is rapidly increasing. Although the etiology of these diseases has not been completely defined, common molecular mechanisms including neuroinflammation, excitotoxicity and mitochondrial dysfunction have been confirmed and can be targeted therapeutically. Moreover, recent studies have shown that endogenous cannabinoid signaling [...]

Lire la suite

A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology, Lisa M. Eubanks et al., 2006

A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology Lisa M. Eubanks, Claude J. Rogers, Albert E. Beuscher IV, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, and Kim D. Janda Molecular Pharmacology, 2006, 3, 6, 773–777. doi:10.1021/mp060066m Abstract : Alzheimer's disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer's disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease progression have become imperative to both improve the quality of life for patients as well as reduce [...]

Lire la suite

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease, C. García, R.G. Pertwee, J. Fernandez-Ruiz et al., 2011

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease C. García, C. Palomo-Garo, M. Garcia-Arencibia, J.A. Ramos, R.G. Pertwee, J. Fernandez-Ruiz British Journal of Pharmacology, 2011, 163, 1495-1506. (Themed Issue : Cannabinoids on Biology and Medicine, Part 1) DOI : 10.1111/j.1476-5381.2011.01278.x   Abstract BACKGROUND AND PURPOSE Previous findings have indicated that a cannabinoid, such as Δ9-THCV, which has antioxidant properties and the ability to activate CB2 receptors but to block CB1, might be a promising therapy for alleviating symptoms and delaying neurodegeneration in Parkinson's disease (PD). EXPERIMENTAL APPROACH The ability of Δ9-THCV to reduce motor inhibition and provide neuroprotection was investigated in rats lesioned with [...]

Lire la suite

Biphasic effects of THC in memory and cognition, Edward J. Calabrese and Alberto Rubio-Casillas, 2018

Biphasic effects of THC in memory and cognition Edward J. Calabrese, Alberto Rubio-Casillas European Journal of Clinical Investigation, 2018, 48, e12920. DOI: 10.1111/eci.12920 Abstract : A generally undesired effect of cannabis smoking is a reversible disruption of short-term memory induced by delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. However, this paradigm has been recently challenged by a group of scientists who have shown that THC is also able to improve neurological function in old animals when chronically administered at low concentrations. Moreover, recent studies demonstrated that THC paradoxically promotes hippocampal neurogenesis, prevents neurodegenerative processes occurring in animal models of Alzheimer’s disease, protects from inflammationinduced [...]

Lire la suite

A chronic low dose of Δ9 tetrahydrocannabinol (THC) restores cognitive function in old mice, Andras Bilkei-Gorzo et al., 2017

A chronic low dose of Δ9 tetrahydrocannabinol (THC) restores cognitive function in old mice Andras Bilkei-Gorzo, Onder Albayram, Astrid Draffehn, Kerstin Michel, Anastasia Piyanova, Hannah Oppenheimer, Mona Dvir-Ginzberg, Ildiko Rácz, Thomas Ulas, Sophie Imbeault, Itai Bab, Joachim L Schultze & Andreas Zimmer Nature Medicine, 2017, 23, 782-787. DOI : 10.1038/nm.4311 Abstract : The balance between detrimental, pro-aging, often stochastic processes and counteracting homeostatic mechanisms largely determines the progression of aging. There is substantial evidence suggesting that the endocannabinoid system (ECS) is part of the latter system because it modulates the physiological processes underlying aging. The activity of the ECS declines during aging, as CB1 receptor expression [...]

Lire la suite

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study, A. Shelef et al., 2016

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study Shelef A., Barak Y., Berger U., Paleacu D., Tadger S., Plopsky I., Baruch Y. Journal of Alzheimer's Disease, 2016, 51, 1, 15-19. DOI: 10.3233/JAD-150915   BACKGROUND : Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE : To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS : Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS : Ten patients completed the trial. Significant reduction [...]

Lire la suite

Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids, Antonio Currais et al., 2016

Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids Antonio Currais, Oswald Quehenberger, Aaron M Armando, Daniel Daugherty, Pam Maher and David Schubert NPJ, Aging and Mechanisms of Disease, 2016, 2, 16012; doi:10.1038/npjamd.2016.12; published online 23 June 2016 Nature Partner Journals;  www.nature.com/npjamd   Abstract : The beta amyloid (Aβ) and other aggregating proteins in the brain increase with age and are frequently found within neurons. The mechanistic relationship between intracellular amyloid, aging and neurodegeneration is not, however, well understood. We use a proteotoxicity model based upon the inducible expression of Aβ in a human central nervous system nerve cell line to characterize a distinct form of nerve [...]

Lire la suite

Prenatal cannabis exposure – The “first hit” to the endocannabinoid system, Kimberlei A. Richardson et al., 2016,

Prenatal cannabis exposure - The “first hit” to the endocannabinoid system Kimberlei A. Richardson, Allison K. Hester, Gabrielle L. McLemore Neurotoxicology and Teratology, 2016, 58, 5-14. DOI : 10.1016/j.ntt.2016.08.003 © 2016 Elsevier Inc. All rights reserved Abstract : As more states and countries legalize medical and/or adult recreational marijuana use, the incidences of prenatal cannabis exposure (PCE) will likely increase. While young people increasingly view marijuana as innocuous, marijuana preparations have been growing in potency in recent years, potentially creating global clinical, public health, andworkforce concerns. Unlike fetal alcohol spectrumdisorder, there is no phenotypic syndrome associated with PCE. There is also no preponderance of evidence that [...]

Lire la suite